Assessing Precigen (PGEN) Valuation After Wider 2025 Loss And Earnings Release

Earnings results bring Precigen’s 2025 performance into focus

Precigen (PGEN) recently reported full year 2025 results, with revenue of US$9.68 million and a net loss of US$250.64 million. The wider loss and revenue figures are likely central to how investors reassess the stock.

See our latest analysis for Precigen.

Precigen’s share price has been volatile, with a 1 day share price return of 19.08% and 7 day return of 23.64%, while the 90 day return shows a decline of 7.42%. This contrasts with a very large 1 year total shareholder return, as investors react to the wider 2025 loss and the upcoming virtual fireside chat.

If Precigen’s swings have your attention, it can help to see how other healthcare names are trading and growing, starting with 34 healthcare AI stocks.

With Precigen trading at US$3.87 and sitting at a very large discount to the consensus price target, along with an intrinsic value estimate that is far above the current price, investors have to ask whether there is a genuine opportunity here or whether the market is already accounting for ambitious future growth.

Most Popular Narrative: 54.5% Undervalued

Precigen’s most followed narrative pegs fair value at $8.50 per share, which sits well above the recent $3.87 close and frames the current discount.

Rapid uptake of PAPZIMEOS in a sizable and previously underserved adult RRP population, combined with strong physician enthusiasm and broad label coverage, supports a multi year ramp in product revenue as pent up demand converts into treated patients.

Read the complete narrative.

Curious what sits behind that optimism on PAPZIMEOS, revenue acceleration, and future margins, and how those ingredients feed into the $8.50 fair value call.

Result: Fair Value of $8.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside story still hinges on PAPZIMEOS sustaining its current traction and pricing. Any slowdown or reimbursement pushback could quickly challenge the $8.50 fair value case.

Find out about the key risks to this Precigen narrative.

Next Steps

With sentiment split between risk and reward, it makes sense to move quickly and test the thesis against the full picture for yourself with 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Precigen has sparked your interest, do not stop here; broaden your watchlist now so you are not the one hearing about the best ideas later.

• Hunt for mispriced quality by scanning 58 high quality undervalued stocks that combine fundamentals with the kind of discount many investors only notice after the move.
• Strengthen your income focus by reviewing 12 dividend fortresses and see which payouts currently offer yield and consistency on the same page.
• Prioritise resilience by checking 64 resilient stocks with low risk scores so potential downside is front of mind before you commit fresh capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com